News Focus
News Focus
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

Re: bridgeofsighs post# 943

Friday, 01/26/2007 5:24:53 PM

Friday, January 26, 2007 5:24:53 PM

Post# of 2446
That analyst is out to lunch, IMO. Visudyne is a barbaric relic; I give it zero chance of making a meaningful comeback.

NVS seems to agree—there was nary a peep about Visudyne in NVS’ long PR announcing the approval of Lucentis in Europe (#msg-16445106).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRDX News